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Inhibition of Natural Killer Cell–Mediated
Cytotoxicity by Kaposi’s Sarcoma–Associated
Herpesvirus K5 Protein
eliminate autologous cells that present quantitative and/
or qualitative alteration of MHC class I molecules (Gar-
rido et al., 1997). On the other hand, activating signals
for NK cells may be initiated by many different adhesion
or costimulatory molecules (Bakker et al., 2000; Bottino
Satoshi Ishido,* Joong-Kook Choi,*
Bok-Soo Lee,* Chunyang Wang,* Maryann DeMaria,†
R. Paul Johnson,† George B. Cohen,‡
and Jae U. Jung*k
*Tumor Virology Division and
et al., 2000). These include LFA-1, CD2, CD16, CD26,† Immunology Division
CD28, CD44, CD69, NKR-P1, 2B4, DNAM-1, NKG2D,New England Regional Primate Research Center
Ly6, CD94, NKp44, NKp46, NKp30, and others (BakkerHarvard Medical School
et al., 2000; Lanier, 2000). In addition, a number of stud-Southborough, Massachusetts 01772
ies have demonstrated that the B7 family and ICAM-1‡AIDS Research Center
can function as ligands for NK cell mediated cytotoxic-
Massachusetts General Hospital ity–activating receptors (Dang et al., 1990; Azuma et al.,
Harvard Medical School 1992; Galea-Lauri et al., 1999; Wilson et al., 1999). The
Charleston, Massachusetts 02129 strength of this response has been shown to override
the negative signaling mediated by interaction between
KIRs and MHC class I molecules (Chambers et al., 1996).
Summary Herpesviruses establish lifelong infections despite the
presence of an active immune system. To achieve this,
Kaposi’s sarcoma–associated herpesvirus (KSHV) K3 viruses have evolved elaborate mechanisms that target
and K5 proteins dramatically downregulate MHC class and modulate different aspects of the host’s immune
system (Ploegh, 1998). A human tumor-associated virus,I molecules. However, although MHC class I downreg-
called Kaposi’s sarcoma-associated herpesvirus (KSHV)ulation may protect KSHV-infected cells from cyto-
or human herpesvirus 8 (HHV8), has been consistentlytoxic T lymphocyte recognition, these cells become
identified in Kaposi’s sarcoma tumors from HIV-positivepotential targets for natural killer (NK) cell–mediated
and HIV-negative patients (Chang et al., 1994; Cesarmanlysis. We now show that K5 also downregulates ICAM-1
et al., 1995; Mesri et al., 1996). KSHV has also beenand B7-2, which are ligands for NK cell–mediated cyto-
identified in primary effusion lymphoma (PEL) and antoxicity receptors. As a consequence, K5 expression
immunoblast variant of Castleman’s disease, which aredrastically inhibits NK cell–mediated cytotoxicity. Con-
of B cell origin (Chang et al., 1994; Cesarman et al.,versely, de novo expression of B7-2 and ICAM-1 resensi-
1995; Renne et al., 1996). The genomic sequence classi-tizes the K5-expressing cells to NK cell–mediated cyto-
fies KSHV as a gamma-2 herpesvirus that is closely
toxicity. This is a novel viral immune evasion strategy related to herpesvirus saimiri (Russo et al., 1996; Neipel
where KSHV K5 achieves immune avoidance by down- et al., 1997) and the recently isolated rhesus monkey
regulation of cellular ligands for NK cell–mediated cy- rhadinovirus (Desrosiers et al., 1997; Rose et al., 1997;
totoxicity receptors. Searles et al., 1999).
Despite the collinearity of genomic structure and the
Introduction similarity of genomic sequence among these gamma-2
herpesviruses, KSHV also contains nonconserved,
Natural killer (NK) cells are a subpopulation of lymphoid unique regions with open reading frames named K3,
cells that do not require prior sensitization to recognize K4.2, K5, and K7 (Russo et al., 1996; Nicholas et al.,
and kill various targets, including viruses, intracellular 1997). K3 and K5 exhibit 40% amino-acid identity to
bacteria, parasites, and neoplastic cells (Karre and each other (Russo et al., 1996; Nicholas et al., 1997)
Welsh, 1997; Unanue, 1997; Lanier, 1998b; Biron et al., and are expressed during the early lytic cycle of viral
1999; Long, 1999). In addition, NK cells produce an array replication (Nicholas et al., 1997; Sun et al., 1999). Both
of cytokines, such as interferon-g, which are involved the K3 and K5 gene products are related to the immedi-
in the elimination of intracellular pathogens as well as ate-early gene (IE1) product of bovine herpesvirus 4 and
in the generation of the antigen-specific immune re- the ORF12 of Herpesvirus saimiri (Nicholas et al., 1997).
sponses. All of these open reading frames contain two C4HC3 zinc
NK cell–mediated cytotoxicity is controlled by a fine finger motifs at the amino terminus and hydrophobic
balance between distinct receptors that mediate inhibi- transmembrane regions in the central region but are of
tory and activating signals (Lanier, 1998b; Long, 1999; varying size in the carboxy-terminal tail (Nicholas et al.,
Bottino et al., 2000). Recent studies have demonstrated 1997). Recently, we have demonstrated that K3 and K5
that the interaction of major histocompatibility complex dramatically downregulate class I molecules. However,
class I (MHC class I) molecules on target cells with killer K3 and K5 differ in their specificity as K3 drastically
inhibitory receptors (KIRs) on NK cells can turn off NK downregulates histocompatibility leukocyte antigen A
cell–mediated cytotoxicity (Lanier, 1998b; Long, 1999; (HLA-A), HLA-B, HLA-C, and HLA-E, whereas K5 exclu-
Blery et al., 2000). In the absence of appropriate interac- sively downregulates HLA-A and HLA-B2 (Ishido et al.,
tion between KIRs and MHC class I molecules, NK cells 2000). This selective downregulation of HLA allotypes
can exert their cytolytic function. Therefore, NK cells by K5 is partly due to differences in amino acid se-
quences in the transmembrane region of HLA. Biochem-
ical analyses have demonstrated that while K3 and K5k To whom correspondence should be addressed (e-mail: jae_ jung@
hms.harvard.edu). do not affect expression and intracellular transport of
Immunity
366
Figure 1. Selective Effects of K3 and K5 on MHC Class I Surface Expression and NK Cytotoxicity
(A) Selective downregulation of HLA allotypes by K5. Live BJAB (-), BJAB/K3 (K3), BJAB/K5 (K5), and BJAB/K3/K5 (K3/5) cells were stained
for the surface expression of HLA-A2, HLA-B13, and HLA-Bw4, and the level of their surface expression was analyzed by flow cytometry (top
figure). Histograms of each HLA staining (dark shaded) are overlaid with isotype antibody control (dotted line). The mean value of the relative
level of surface expression of each lymphocyte antigen is presented inside of the figure. To examine level of HLA-Cw4 expression, lysates
corresponding to 1 3 105 BJAB (-), BJAB/K3 (K3), BJAB/K5 (K5), and BJAB/K3/K5 (K3/5) were used for immunoblot analysis (bottom figure).
Immunoblot detection was performed with a 1:500 dilution of primary L31 antibody, which reacted only with the denatured forms of HLA-
Cw4 (Setini et al., 1996; Giacomini et al., 1997).
(B) Effects of K3 and K5 on YTS cell–mediated cytotoxicity. YTS NK and YTS.NKIR2DL1 cells were mixed with BJAB (-), BJAB/K3 (K3), BJAB/
K5 (K5), and BJAB/K3/K5 (K3/K5) target cells at E:T ratio (2:1) for 6 hr.
(C) Effects of K3 and K5 on NKL cell–mediated cytotoxicity. NKL cells were mixed with BJAB (-), BJAB/K3 (K3), BJAB/K5 (K5), and BJAB/K3/
K5 (K3/K5) target cells at E:T ratio (10:1) for 6 hr. NK cell cytotoxicity was measured by two different flow cytometry analyses: reduction in
light-scattering signal of lysed target cells or the PI uptake for dead target cells. Both assays showed essentially the same results. Values
represent the average of two independent experiments.
class I molecules, their expression induces rapid endo- 2000). The EBV- and KSHV-negative Burkitt’s lymphoma
cell line BJAB has been shown to express HLA-A1, HLA-cytosis of class I molecules (Ishido et al., 2000).
In this report, we demonstrate that in addition to MHC A2, HLA-B13, HLA-B35, HLA-Bw4, HLA-Bw6, and HLA-
Cw4 (Spring et al., 1985). Consistent with the previousclass I molecules, K5 downregulates ICAM-1 and B7-2,
which are ligands for NK cell–mediated cytotoxicity re- results (Ishido et al., 2000), stable expression of K3 in
BJAB cells drastically downregulated HLA-A2, HLA-ceptors. As a consequence, K5 expression strongly in-
hibits NK cell–mediated cytotoxicity. Thus, KSHV con- B13, HLA-Bw4, and HLA-Cw4, whereas stable expres-
sion of K5 downregulated HLA-A2, HLA-B13, and HLA-tains a unique gene product to protect virus-infected
cells from destruction by innate immune effector cells. Bw4 but not HLA-Cw4 (Figure 1A).
HLA-A and HLA-B proteins are primarily responsible
for presenting processed antigen peptides to cytotoxicResults
T lymphocytes (CTLs), whereas HLA-C and HLA-E are
the predominant class I proteins responsible for pre-Inhibition of YTS NK Cell–Mediated
venting NK cells from killing lymphoid cells (Lanier,Cytotoxicity by K5
1998a; Leibson, 1998; Yokoyama, 1998). This suggestsDespite their sequence identity and functional similarity,
that the indiscriminate downregulation of HLA-C andK3 and K5 exhibit differences in their specificities of
HLA-E by K3 may invite NK cells to attack K3-expressingMHC class I downregulation; K3 drastically downregu-
cells. To examine the effect of K3 and K5 on NK celllates HLA-A, HLA-B, HLA-C, and HLA-E, whereas K5
preferentially downregulates HLA-A and -B (Ishido et al., cytotoxicity, the NK cell line YTS was tested for its abil-
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Figure 2. Downregulation of B7-2 and ICAM-1
Surface Expression by K5
Live BJAB (2), BJAB/K3 (K3), BJAB/K5 (K5),
and BJAB/K3/K5 (K3/K5) cells were stained
for the surface expression of B7-2, ICAM-1,
ICAM-2, and ICAM-3. Histograms of each
lymphocyte antigen staining (dark shaded)
are overlaid with isotype antibody control
(dotted line). The mean value of the relative
level of surface expression of each lympho-
cyte antigen is presented inside of the figure.
ity to kill BJAB, BJAB/K3, or BJAB/K5 target cells. YTS et al., 2000), we investigated whether K5 expression
NK cells, established from a patient with acute lympho- overrode the susceptibility of K3-expressing cells to NK
blastic lymphoma (Yodoi et al., 1985), do not express cell cytotoxicity. For this, BJAB/K3 cells were electro-
KIRs and therefore kill target cells in an MHC class porated with a K5 expression vector and selected by
I–unrestricted fashion. In contrast, a YTS derivative, growth in medium containing 500 mg/ml of hygromycin.
YTS.NKIR2DL1, stably expresses the NK inhibitory re- While K5 did not significantly alter expression of HLA-
ceptor KIR2DL1 on its surface (Cohen et al., 1999). A2, HLA-B13, HLA-Bw4, and HLA-Cw4 on BJAB/K3 cells
KIR2DL1 specifically binds to a subset of HLA-C mole- (Figure 1A), it strongly conferred resistance of BJAB/K3
cules including HLA-Cw2, HLA-Cw4, HLA-Cw-5 and cells to cytotoxicity by YTS and YTS.NKIR2DL1 cells
HLA-Cw6; therefore, YTS.NKIR2DL1 is selectively inhib- (Figure 1B). Consistent with results from stable expres-
ited from killing target cells that express these class I sion assays, transient expression of K5 also strongly
molecules (Cohen et al., 1999). NK cytotoxicity of target protected BJAB/K3 cells from cytotoxicity by YTS and
cells was monitored by 35S-release and flow cytometry YTS.NKIR2DL1 cells (data not shown).
assays. Flow cytometry assay was based on the reduc- Additional NK cells, NKL cells, were used to further
tion in light-scattering signal of cells as they die or by examine the effect of K3 and K5 expression on NK cell–
the uptake of the fluorescent dye propidium iodide (PI), mediated cytotoxicity. Similar to activated primary NK
which is specific for dead cells. Lysis of BJAB cells by cells, NKL cells are interleukin-2 (IL-2) dependent,
YTS cells in these assays occurred at effector-to-target CD32CD161CD282CD56dim, and can mediate both natu-
ratios (1:1 to 6:1) and within incubation time (3–6 hr) com- ral killing and antibody-dependent cellular cytotoxicity
parable to that of 35S-release assays (data not shown). (Robertson et al., 1996). While both BJAB and BJAB/K5
Because BJAB cells are HLA-Cw4 positive (Spring et cells were equally resistant to NKL cytotoxicity, BJAB/
al., 1985), they were relatively resistant to cytotoxicity K3 cell were highly sensitive to NKL cytotoxicity (Figure
by YTS.NKIR2DL1 cells but were highly sensitive to cyto- 1C). However, K5 expression in BJAB/K3 cells conferred
toxicity by YTS cells (Figure 1B). Downregulation of HLA- resistance to NKL cell–mediated cytotoxicity (Figure
Cw4 by K3 rendered BJAB/K3 cells markedly sensitive 1C). These results demonstrate that drastic downregula-
to recognition by YTS.NKIR2DL1 cells, and these cells
tion of MHC class I alleles by K3 results in increasedwere also efficiently lysed by YTS cells (Figure 1B). In
susceptibility to NK cell cytotoxicity and that K5 expres-contrast, the HLA-Cw4 left on the surface of BJAB/K5
sion confers resistance on K3-expressing cells to NKcells appeared to protect these cells from lysis by
cell–mediated cytotoxicity.YTS.NKIR2DL1 cells (Figure 1B). However, surprisingly,
we found that BJAB/K5 cells were also resistant to lysis
Downregulation of B7-2 and ICAM-1 by K5by YTS cells (Figure 1B). This suggests that K5 might
Because YTS cell–mediated killing is not inhibited bybe influencing NK cell killing through mechanisms out-
MHC class I surface expression, the inhibitory effect ofside of HLA-C expression since YTS cell killing is not
K5 on NK cell cytotoxicity was probably mediated byinhibited by HLA-C expression.
molecules other than those of MHC class I. To delineate
the mechanism of K5-mediated inhibition on NK cellK5 Expression Confers the Resistance of BJAB/K3
cytotoxicity, the surface expression of additional lym-Cells to NK Cell Cytotoxicity
phocyte antigens was examined on BJAB, BJAB/K3,Since KSHV K3 and K5 are expressed at similar time
points in the viral lytic cycle (Nicholas et al., 1997; Haque BJAB/K5, and BJAB/K3/K5 cells. In addition to MHC
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Figure 3. Downregulation of B7-2 and ICAM-1 Surface Expression by K5
(A) Downregulation of B7-2 and ICAM-1 by K5. BJAB cells were electroporated with GFP (control), GFP-K3 (K3), GFP-K5 (K5), GFP-K5/mZn
(K5/mZn), or GFP-K5/DC (K5/DC) vector. Cell surface levels of B7-2 and ICAM-1 were assessed 48 hr posttransfection by staining for B7-2
or ICAM-1 with their specific antibodies (y axis) and gating the GFP-positive cell population (x axis) by flow cytometry. The numbers inside
the boxes indicate the average mean value of B7-2 or ICAM-1 surface expression of the GFP-positive cell population. The data were reproduced
in two independent experiments.
(B) Expression of K5 and its mutants. BJAB cells were electroporated with GFP (lane 1), GFP-K5 (lane 2), GFP-K5/mZn (lane 3) or GFP-K5/
DC (lane 4) vector. Forty-eight hours after electroporation, cells were labeled with [35S]methionine and [5S]cysteine overnight, cell lysates were
subjected to an immunoprecipitation with an anti-6xHis antibody, and autoradiography was developed by Fuji Phospho Imager. Bars indicated
K5 and its mutants.
class I molecules, B7-2 and ICAM-1 molecules were K3, K5/mZn, and K5/DC did not affect B7-2 and ICAM-1
expression under the same conditions (Figure 3A). K5/drastically downregulated in BJAB/K5 and BJAB/K3/K5
cells compared to BJAB and BJAB/K3 cells (Figure 2). mZn and K5/DC mutants were expressed at the equiva-
lent level to wild-type (wt) K5 in these cells (Figure 3B).The downregulation of ICAM-1 by K5 was specific be-
cause the surface expression level of ICAM-2 and ICAM-3 Thus, these results demonstrate that transient and sta-
ble expression of K5 but not K3 downregulates B7-2was not affected in these same cell lines (Figure 2). In
addition, no detectable change was observed in surface and ICAM-1 and that the putative Zn binding motif and
carboxyl cytoplasmic region of K5 are required for thisexpression of CD11a, CD18, CD19, CD20, CD22, CD29,
CD49d, CD62, or MHC class II (data not shown). B7-1 activity.
was not expressed at a detectable level in these cells
(data not shown). To further demonstrate the specific
downregulation of B7-2 and ICAM-1 by K5, BJAB cells Transmembrane and Cytoplasmic Regions of B7-2
and ICAM-1 Are Necessary for an Efficientwere electroporated with GFP, GFP-K3, or GFP-K5 ex-
pression vectors. Mutant forms of K5 were also included Downregulation by K5
We have previously demonstrated that the transmem-in this assay; the K5/mZn mutant contains replacements
of cysteines in the putative Zn binding motifs with ser- brane and cytoplasmic regions of MHC class I molecules
are necessary for K3- and K5-mediated downregulationines, and the K5/DC mutant contains a deletion of the
carboxyl cytoplasmic region. The effect of expression (Ishido et al., 2000). To identify the region of B7-2 and
ICAM-1 that accounted for K5-mediated downregula-of K5 and its mutants on the cell-surface levels of B7-2
and ICAM-1 was assessed 48 hr posttransfection in the tion, we constructed CD8 chimeric versions of B7-2 and
ICAM-1. B7-2/CD8 and ICAM-1/CD8 chimeras con-GFP-positive cell population by flow cytometry. K5 ex-
pression induced approximately 6- to 10-fold downregu- tained the extracellular regions of B7-2 and ICAM-1
joined to the transmembrane (Tm) and cytoplasmic taillation of ICAM-1 and B7-2, respectively, whereas GFP,
Inhibition of NK Cell Killing by KSHV K5
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Figure 4. Transmembrane and Cytoplasmic
Regions of B7-2 and ICAM-1 Are Necessary
for Efficient Downregulation by K5
BJAB and BJAB/K5 cells were electroporated
with GFP-B7-2 (B7-2), GFP-B7-2/CD8 (B7-2/
CD8), GFP-ICAM-1 (ICAM-1), or GFP-ICAM-
1/CD8 (ICAM-1/CD8) vector. Cell surface lev-
els of B7-2 and ICAM-1 were assessed 48
hr posttransfection by staining for B7-2 or
ICAM-1 with their specific antibodies (y axis)
and gating for the GFP-positive cell popula-
tion (x axis) by flow cytometry. The data were
reproduced in two independent experiments.
region of CD8a. Forty-eight hours after electroporation to MHC class I molecules, the transmembrane and cyto-
plasmic regions of B7-2 and ICAM-1 are necessary forof a GFP vector containing wt B7-2, the B7-2/CD8 chi-
mera, wt ICAM-1, or the ICAM-1/CD8 chimera into BJAB an efficient downregulation by K5.
and BJAB/K5 cells, the surface levels of B7-2 and ICAM-1
were assessed on the GFP-positive cell population by
flow cytometry. Transfection of BJAB/K5 cells with B7-2/ Expression of B7-2 and ICAM-1 on K5-Expressing
Cells Induces Efficient Killing by NK CellsCD8 or ICAM-1/CD8 chimeras resulted in a dramatic
increase in B7-2 or ICAM-1 surface expression, whereas The B7 family and ICAM-1 have been shown to function
as ligands for activating NK receptors that promote NKtransfection of wt B7-2 or wt ICAM-1 resulted in hetero-
geneous surface expression of B7-2 and ICAM-1 (Figure cell–mediated cytotoxicity (Dang et al., 1990; Azuma et
al., 1992; Chambers et al., 1996; Galea-Lauri et al., 1999;4). In contrast, transfection of either wt or CD8 chimeric
forms of B7-2 and ICAM-1 into BJAB cells resulted in Martin-Fontecha et al., 1999; Wilson et al., 1999). Disrup-
tion of the interaction of ICAM-1/LFA-1 and B7/CD28 ora significant increase in B7-2 and ICAM-1 surface ex-
pression (Figure 4). These results suggested that similar its derivatives between NK and target cells inhibits NK
Figure 5. The Role of B7-2 and ICAM-1 in NK Cell–Mediated Cytotoxicity
(A) B7-2 expression induces an efficient cytotoxicity of NK cells. Forty-eight hours after electroporation with GFP (control), GFP-ICAM-1/CD8
(ICAM/CD8), or GFP-B7-2/CD8 (B7-2/CD8), BJAB/K5 cells were mixed with YTS cells at E:T ratio (2:1) for 6 hr, followed by staining with Cy-
chrome-conjugated CD19 antibody, PE-conjugated B7-2, or PE-conjugated ICAM-1 antibody. CD19/GFP-positive cells, CD19/GFP/ICAM-1-
positive cells, and CD19/GFP/B7-2-positive cells as indicated by boxes were separated from untransfected BJAB/K5 and YTS cells by flow
cytometry. NK cell cytotoxicity is displayed as the percent of reduction of CD19/GFP-positive population (box) of BJAB/K5 cells after 6 hr
incubation with YTS cells.
(B) Synergistic effect of B7-2 and ICAM-1 on NK cell–mediated cytotoxicity. Forty-eight hours after electroporation with pBud-B7/ICAM
expression vector, BJAB/K5 cells were mixed with YTS cells at E:T ratio (2:1) for 6 hr, followed by staining with Cy-chrome-conjugated CD19
antibody, FITC-conjugated B7.2, and PE-conjugated ICAM-1 antibody. CD19/B7-2/ICAM-1-positive population of BJAB/K5 cells was indicated
by box. NK cell cytotoxicity is displayed as the percent of reduction of CD19/ICAM-1 or CD19/B7-2 double-positive population (box) of BJAB/
K5 after 6-hr incubation with YTS cells. The data were reproduced in three independent experiments.
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Figure 6. Synergistic Effects of B7-2 and
ICAM-1 Expression on NK Cell–Mediated Cy-
totoxicity
(A) Surface expression of B7-2 and ICAM-1.
Live BJAB/K5 (K5), BJAB/K5-ICAM-1/CD8
(K5/ICAM-1), BJAB/K5-B7-2/CD8 (K5/B7-2),
and BJAB/K5-B7-2/ICAM-1 (K5/B7-2/ICAM-1)
cells were stained for the surface expression
of B7-2 and ICAM-1. The mean value of the
relative levels of surface expression of B7-2
(upper left quadrant) and ICAM-1 (lower right
quadrant) is presented inside of the figure.
(B) Synergistic effects of B7-2 and ICAM-1
expression on NK cell–mediated cytotoxicity.
Target cells were mixed with YTS cells at E:T
ratio (2:1) for 6 hr, followed by staining with
Cy-chrome-conjugated CD19 antibody. NK
cell cytotoxicity is displayed as the percent
of reduction of CD19-positive cells after 6 hr
incubation with YTS cells. The data were re-
produced in two independent experiments.
cell cytotoxicity, whereas de novo B7 and ICAM-1 ex- further enhanced the level of susceptibility of BJAB/K5
cells to YTS cytotoxicity (Figure 6B). Thus, these resultspression on target cells induces NK cell killing (Dang et
demonstrate that B7-2 and ICAM-1 exhibit a synergistical., 1990; Azuma et al., 1992; Galea-Lauri et al., 1999;
effect on NK cell–mediated cytotoxicity and that theWilson et al., 1999). To determine whether the resistance
high degree of resistance of K5-expressing cells to NKof BJAB/K5 cells to NK cell–mediated cytotoxicity was
cytotoxicity is most likely due to downregulation of B7-2due to downregulation of B7-2 and/or ICAM-1 surface
and ICAM-1 surface expression.expression, BJAB/K5 cells were electroporated with
GFP, GFP-B7-2/CD8, or GFP-ICAM-1/CD8 and then in-
The Role of B7-2 and ICAM-1 in the Activationcubated with YTS NK cells. B7-2 surface expression on
of NK Cell–Mediated CytotoxicityBJAB/K5 cells induced susceptibility to YTS cytotoxic-
The role of B7-2 and ICAM-1 in the activation of NKity, whereas ICAM-1 surface expression did not (Figure
cell–mediated cytotoxicity was further assessed by anti-5A). These results indicate that B7-2 likely plays an im-
body blocking experiments. BJAB and BJAB/K3 cellsportant role in activation of YTS cytotoxicity as pre-
were selected because of their sensitivity to YTS andviously reported (Azuma et al., 1992).
NKL cytotoxicity. BJAB and BJAB/K3 cells were prein-
cubated with IgG1 isotype antibodies specific for B7-2Synergistic Effects of B7-2 and ICAM-1 Expression
and ICAM-1 and then mixed with YTS or NKL cells,on NK Cell–Mediated Cytotoxicity
respectively. The same amount of a mouse IgG1 wasTo examine potential synergistic effects of B7-2 and
added as a control. While preincubation with an anti-ICAM-1 surface expression on NK cell–mediated cyto-
ICAM-1 antibody only weakly inhibited YTS cytotoxicity,toxicity, a pBud-B7/ICAM vector was constructed that
preincubation of BJAB cells with an anti-B7-2 antibody
expressed both B7-2/CD8 and ICAM-1/CD8 chimeras inhibited YTS cytotoxicity to a significant degree. Fur-
from two independent promoters. Following transfec- thermore, preincubation with both anti-B7-2 and anti-
tion with pBud-B7/ICAM, surface expression of B7-2 ICAM-1 antibodies synergistically enhanced the level of
and ICAM-1 were readily detected at levels comparable inhibition of YTS cytotoxicity (Figure 7A). In contrast,
to those of cells transfected with GFP-B7-2/CD8 or GFP- preincubation with ICAM-1 antibody blocked NKL cyto-
ICAM-1/CD8 individually (data not shown). When these toxicity as efficiently as with B7-2 antibody (Figure 7B).
cells were used in an NK cytotoxicity assay, more than Also, preincubation with both antibodies synergistically
95% of B7-2- and ICAM-1-positive BJAB/K5 cells were enhanced the level of inhibition of NKL cytotoxicity (Fig-
efficiently lysed by YTS cells (Figure 5B). ure 7B). A control mouse IgG1 did not affect YTS and
To further demonstrate the role of B7-2 and ICAM-1 NKL cytotoxicity under the same conditions. These re-
expression in NK cell–mediated cytotoxicity, BJAB/K5 sults suggest that ICAM-1 exerts a significant effect on
cells were electroporated with pBud-B7-2/CD8, pBud- the activation of NKL cytotoxicity, whereas B7-2 plays
ICAM-1/CD8, or pBud-B7-2/ICAM-1 and selected by an important role in the activation of both YTS and NKL
growth in medium containing 400 mg/ml of zeosin. By cytotoxicity. These results further support the idea that
flow cytometry analysis, a significantly elevated level of the inhibitory effect of K5 on NK cell–mediated cytotox-
B7-2 and/or ICAM-1 surface expression was detected icity is mediated through the downregulation of ICAM-1
and B7-2 surface expression.on the stably transfected cells compared to that of
BJAB/K5 cells (Figure 6A). Consistent with results from
transient expression assays, stable expression of B7-2 Discussion
made BJAB/K5 cells susceptible to YTS cytotoxicity,
whereas stable expression of ICAM-1 did not (Figure We have previously reported that the KSHV K3 and K5
zinc finger proteins drastically downregulate MHC class6B). In addition, coexpression of both B7-2 and ICAM-1
Inhibition of NK Cell Killing by KSHV K5
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antibodies. Because B7-2 plays an important role in the
activation of CD28-negative NKL cell–mediated cytotox-
icity, ours and the other previous studies suggest that
NK cells may, at least in part, use receptors other than
CD28 and CTLA-4 in their interaction with the B7 family.
In addition, ICAM-1 on antigen-presenting cells has
been shown to contribute to antigen-specific T cell acti-
vation and NK cell–mediated cytotoxicity (Dang et al.,
1990; Sprent, 1999; Hwang et al., 2000). Consistent with
these reports, we demonstrate that B7-2 surface expres-
sion renders K5-expressing cells susceptible to YTS
cytotoxicity and that ICAM-1 surface expression further
enhances this activity. This suggests that an interaction
between LFA-1 and ICAM-1 adhesion molecules may
bring B7-2 and CD28/its derivatives to closer proximity
on the surface and stabilize the absorption of positive
signalings mediated by B7-2. In addition, synergistic co-
stimulation by B7-2 and ICAM-1 may be necessary to over-
ride the strength of the negative signaling mediated by
interaction between KIRs and MHC class I molecules.
KSHV is the long-sought etiologic agent for Kaposi’s
sarcoma and pleural effusion lymphoma in which pri-
mary virus-harboring, proliferating cells are of endothe-
lial and B cell origin, respectively (Ganem, 1997; Schulz
Figure 7. Inhibition of NK Cell–Mediated Cytotoxicity by B7-2 and et al., 1998). Consistent with our finding, MHC class I
ICAM-1 Antibody expression of KSHV-infected primary effusion lym-
After BJAB cells were preincubated with 5 mg/ml of anti-B7-2 mouse phoma BCBL-1 cells is downregulated during the early
IgG1 antibody or anti-ICAM-1 mouse IgG1 antibody individually or lytic cycle of virus replication in which K3 and K5 are
together for 30 min in ice, BJAB cells were mixed with YTS cells at expressed (unpublished data). However, surface ex-
E:T ratio (2:1) for 6 hr (A) or BJAB/K3 cells were mixed with NKL pression of B7-2 and ICAM-1 on BCBL-1 cells could
cells at E:T ratio (10:1) for 8 hr (B), followed by staining with Cy- not be ascertained since neither B7-2 nor ICAM-1 was
chrome-conjugated CD19 antibody. As a control, 5 mg/ml of a mouse
detectable on these cells in the presence or absence ofIgG1 was included. NK cell cytotoxicity is displayed as the percent
viral replication. While B7-2 and ICAM-1 on B lympho-of reduction of CD19-positive BJAB or BJAB/K3 cells after incuba-
cytes are important ligands for activation of NK cell–tion with YTS or NKL cells.
mediated cytotoxicity, ICAM-1 may exhibit a significant
effect on additional cell types such as endothelial cells.
I molecules (Ishido et al., 2000). In this report, we further Upon infection or inflamation, endothelial cells upregu-
demonstrate that downregulation of ICAM-1 and B7-2 late ICAM-1, which can make them more susceptible to
by K5 results in a strong inhibition of NK cell–mediated CTL and NK cells bearing LFA-1 (Patarroyo et al., 1990).
cytotoxicity. These results suggest that downregulation This suggests that besides MHC class I molecules, K5
of B7-2 and ICAM-1 by KSHV K5 may confer protection may target ICAM-1 and B7-2 to protect virus-infected
from NK cell–mediated cytotoxicity upon KSHV-infected endothelial and B cells from NK cell–mediated cytotox-
cells. icity.
NK cell–mediated cytotoxicity is regulated by oppos- Viruses have been shown to use diverse mechanisms
ing signals from receptors that activate or inhibit effector to interfere with cellular immunity. HIV selectively down-
function (Lanier, 1998b; Long, 1999; Bottino et al., 2000). regulates the class I molecules most important for pre-
It is well established that the interaction between KIRs sentation of antigens to CTL, HLA-A, and HLA-B, but
on NK cells and their specific HLA class I allotypes leaves on the cell surface HLA-C and HLA-E, the class
on target cells provides the major turn-off signal that I molecules most important for NK cell inhibition (Cohen
regulates NK cell–mediated cytotoxicity (Lanier, 1998b; et al., 1999). In contrast, human cytomegalovirus (HCMV)
Long, 1999; Blery et al., 2000). Thus, the loss of MHC uses a highly complex strategy to prevent class I presen-
class I molecules from the cell surface renders target tation and NK cell killing. HCMV has four glycoproteins,
cells susceptible to NK cell cytotoxicity. Consistent with US2, US3, US6, and US11, all of which downregulate
this, we have shown here that cells whose MHC class class I–mediated antigen presentation (Ploegh, 1998;
I surface expression is reduced by K3 are highly suscep- Miller and Sedmak, 1999). In addition, HCMV and mouse
tible to NK cell–mediated cytotoxicity. CMV (MCMV) encode a glycoprotein, designated UL18
In contrast, the nature of the molecular mechanisms for HCMV and M144 for MCMV, with homology to the
that provide the signals responsible for NK cell activa- MHC class I heavy chain (Beck and Barrell, 1988; Farrell
tion have remained elusive until recently (Bakker et al., et al., 1997; Reyburn et al., 1997). UL18 associates with
2000). A number of studies have demonstrated that mem- leukocyte immunoglobulin-like receptor-1 (LIR-1), which
bers of the B7 family can function as ligands for activat- is related to KIR. This interaction has been proposed to
ing receptors to induce NK cell–mediated cytotoxicity function as an indirect mechanism capable of blocking
(Dang et al., 1990; Azuma et al., 1992; Galea-Lauri et al., lysis of virus-infected cells by NK cells (Beck and Barrell,
1999; Wilson et al., 1999). Furthermore, these studies 1988; Farrell et al., 1997; Karre and Welsh, 1997; Chap-
have also demonstrated that the B7-mediated triggering man et al., 1999). In addition, HCMV UL40 has been
signal occurs even in the absence of CD28 and CTLA-4 shown to provide the leader sequence for HLA-E surface
expression, suggesting a novel inhibitory mechanism ofand cannot be blocked by anti-CD28 or anti-CTLA-4
Immunity
372
MHC class I, FH0037 antibody for HLA-A2, 00044HA antibody forNK cell killing (Tomasec et al., 2000). Here, we have
HLA-B13, FH0007 antibody for HLA-Bw4, L31 antibody for HLA-shown that KSHV has also evolved a novel immune
Cw4, H111 antibody for CD11a, 6.7 antibody for CD18, B43 antibodyevasion mechanism mediated by similar but distinct
for CD19, 2H7 antibody for CD20, HIB22 antibody for CD22, HUTS-genes, K3 and K5. Because the magnitude of K3 down-
21 antibody for CD29, 9F10 antibody for CD49d, Dreg 56 antibody
regulation of class I molecules is more pronounced than for CD62L, L307.4 antibody for B7–1, IT2.2 antibody for B7-2, TU39
that of K5 (Ishido et al., 2000), K3 may play a major role antibody for MHC class II, 15.2 antibody for ICAM-1, B-T1 antibody
in the inhibition of CTL cytotoxicity. During this process, for ICAM-2, ICAM3.3 antibody for ICAM-3, and goat anti-mouse
however, indiscriminate downregulation of HLA allo- total IgG antibody for isotype control.
types by K3 invites susceptibility to NK cells. To prevent
this, KSHV K5, which may have arisen via a gene-dupli- NK Cytotoxicity
cation event, downregulates B7-2 and ICAM-1, the re- NK cytotoxicity of target cells was assessed by the flow cytometry
sult of which is inhibition of NK cell–mediated cytotoxic- assay based on the decreased light-scattering signal of cells as
they die or by the uptake of propidium iodide (PI), which is specificity. Thus, KSHV harbors two highly related genes, K3
for dead cells (Cohen et al., 1999). Target cells were mixed with NKand K5, with overlapping expression kinetics and similar
cells at E:T ratio (2:1 or 10:1) for 6 hr and were stained with an anti-but distinct functions to ensure comprehensive protec-
CD19 antibody to separate target cells from NK cells by a FACStion from host immune effectors.
Scan (Becton Dickinson Co., Mountainview, CA). Blocking of B7-2Through our efforts to delineate molecular mecha-
and/or ICAM-1 was done using 5 mg of mAb mixed with BJAB cells
nisms of MHC class I, B7-2, and ICAM-1 downregulation on ice for 30 min prior to incubation with NK cells. NK cell cytotoxicity
by K3 and K5, we have found that K5 specifically inter- is displayed as the percent of reduction of target cells after 6-hr
acts with cellular filamins (unpublished data). Filamins incubation with NK cells. In addition, the Live/DEAD Cell–Mediated
form homodimers and contain an N-terminal actin bind- Cytotoxicity Kit (Molecular Probe, Eugene, OR) was also used to
measure the uptake of the PI fluorescent dye, which is specific foring domain that is followed by 24 repeats each of 96
dead cells. Briefly, 1 3 106 target cells were labeled with DiOC18amino acids (Gorlin et al., 1990; Takafuta et al., 1998).
for 20 min, washed with PBS, and incubated with 2 3 106 NK cellsFilamins have been shown to link resident cell surface
for 6 hr. Cells were then counterstained with PI solution to label deadproteins to underlying actin filaments (Ohta et al., 1991;
cells. Cytotoxicity was measured by a FACSvantage flow cytometer.Sharma et al., 1995; Loo et al., 1998; Ott et al., 1998;
Takafuta et al., 1998; Thompson et al., 2000). Tethering
Plasmid Constructionof these resident cell surface molecules by filamins is
The putative zinc finger (mZn) and DC mutations in the K5 geneapparently required for their ligand-dependent re-
were generated with polymerase chain reaction (PCR) using oligonu-arrangement of the cytoskeleton upon association with
cleotide-directed mutagenesis (Du et al., 1995). The K5/mZn mutant
leukocyte activation (Cunningham et al., 1996; Glogauer contained the replacements of the cysteine residues at 15, 56, and
et al., 1998) and for their intracellular trafficking (Liu 59 with serine residues; the K5/DC mutant contained the deletion of
et al., 1997). In fact, signaling by ICAM-1 and LFA-1 the carboxyl 104 amino acids. After each K5 mutant was completely
interaction requires the integrity of the actin-based cy- sequenced to verify the presence of the mutation and the absence
of any other changes, it was subcloned into the GFP expressiontoskeleton (Geginat et al., 2000). Thus, we hypothesize
vector pTRACER-EF (Invitrogen, San Diego, CA). The extracellularthat KSHV K5 targets cellular filamins to disturb a cellular
regions of B7-2 and ICAM-1 were amplified by PCR and fused inactin-based cable network and that this disturbance
frame to the human CD8a fragment containing its transmembraneresults in downregulation of certain lymphocyte surface
and cytoplasmic region. After confirmation of the DNA sequence,proteins that transduce signals for host immune surveil-
the DNA fragment containing the B7-2/CD8 chimera or ICAM-1/
lance. Therefore, a more detailed study of the mecha- CD8 chimera sequence was cloned into the pTRACER-EF vector or
nism by which KSHV K5 downregulates ICAM-1 and pBud-CED4 vector (Invitrogen, San Diego, CA). Wt B7-2 and wt
B7-2 may lead to a better understanding of not only ICAM-1 were also cloned into the pTRACER-EF vector for ex-
how a virus escapes from host immune responses but pression.
also how the cell surface level expression of these im-
portant adhesion molecules is regulated. Metabolic Labeling, Immunoprecipitation, and Immunoblot
For metabolic labeling, cells were rinsed three times with PBS,
washed once with labeling medium (RPMI minus methionine andExperimental Procedures
cysteine plus 10% dialyzed fetal calf serum), and then incubated
with 5 ml of the same medium containing 100 mCi of [35S]methionineCell Culture and Transfection
and [35S]cysteine (New England Nuclear, Boston, MA) for 16 hr. CellsBJAB, YTS, and YTS.NKIR2DL cells (Cohen et al., 1999) were grown
were harvested and lysed with lysis buffer (0.15 M NaCl, 1% Nonidetin RPMI medium supplemented with 10% fetal calf serum. NKL cells
P-40 [NP40]) containing 1 mM Na2VO3, 1 mM NaF, and proteasewere grown in RPMI medium supplemented with 10% (v/v) fetal-
inhibitors (leupeptin, aprotinin, PMSF, and bestatin). Immunoprecip-calf serum and 1000 U/ml recombinant interleukin-2 (GIBCO–BRL,
itation was performed with 1:500 diluted antibody together with 30Grand Island, NY). The pEF1- and pTRACER-derived expression
ml of protein A/G agarose beads. For protein immunoblots, polypep-vector (Invitrogen, San Diego, CA) was introduced into BJAB cells
tides in cell lysates corresponding to 105 cells were resolved byby electroporation at 250 V and 960 mF in serum-free DME medium.
SDS-PAGE and transferred to a nitrocellulose membrane filter. Im-After a 48 hr incubation, the cells were cultured with selection me-
munoblot detection was performed with a 1:500 dilution of primarydium containing 2 mg/ml of G418, 500 mg/ml of hygromycin, or 400
L31 antibody (Setini et al., 1996; Giacomini et al., 1997) using the en-mg/ml of zeosin for 5 weeks.
hanced chemiluminescence system (ECL; Amersham, Chicago, IL).
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